Fay, A., Fizazi, K., Matsubara, N., Azad, A. A., Saad, F., De Giorgi, U., . . . Agarwal, N. (2025). First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: Patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. The lancet. Oncology, 26(4), . https://doi.org/10.1016/S1470-2045(25)00031-2
Chicago-Zitierstil (17. Ausg.)Fay, André, et al. "First-line Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide in Men with Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations: Patient-reported Outcomes from the Randomised, Double-blind, Placebo-controlled, Phase 3 TALAPRO-2 Trial." The Lancet. Oncology 26, no. 4 (2025). https://doi.org/10.1016/S1470-2045(25)00031-2.
MLA-Zitierstil (9. Ausg.)Fay, André, et al. "First-line Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide in Men with Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations: Patient-reported Outcomes from the Randomised, Double-blind, Placebo-controlled, Phase 3 TALAPRO-2 Trial." The Lancet. Oncology, vol. 26, no. 4, 2025, https://doi.org/10.1016/S1470-2045(25)00031-2.